Page 174 - Read Online

Nag et al. J Cancer Metastasis Treat 2020;6:16 I http://dx.doi.org/10.20517/2394-4722.2020.23 Page 11 of 13

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Siegel RL, Jemal A, Wender RC, Gansler T, Ma J, et al. An assessment of progress in cancer control. CA Cancer J Clin 2018;68:329-39.
2. Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, et al. Safety and antitumor activity of apalutamide (ARN-509) in
metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin Cancer Res 2017;23:3544-
51.
3. Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, et al. Androgen receptor mutations in patients with castration-resistant prostate
cancer treated with apalutamide. Ann Oncol 2017;28:2264-71.
4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy.
N Engl J Med 2012;367:1187-97.
5. Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, et al. Prostate cancer incidence in 43 populations worldwide: an analysis
of time trends overall and by age group. Int J Cancer 2016;138:1388-400.
6. Berish RB, Ali AN, Telmer PG, Ronald JA, Leong HS. Translational models of prostate cancer bone metastasis. Nat Rev Urol
2018;15:403-21.
7. Clarke NW, Hart CA, Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 2009;11:57-67.
8. Yoshida T, Kinoshita H, Taniguchi H, Yanishi M, Sugi M, et al. A randomized, open-label, controlled trial of monthly oral minodronate or
semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the prevention
of osteopenia with minodronate and denosumab (PROMADE) study. Osteoporos Int 2020;31:1251-9.
9. Deantoni CL, Fodor A, Cozzarini C, Fiorino C, Brombin C, et al. Prostate cancer with low burden skeletal disease at diagnosis: outcome
of concomitant radiotherapy on primary tumor and metastases. Br J Radiol 2020;93:20190353.
10. DiNatale A, Fatatis A. The bone microenvironment in prostate cancer metastasis. Adv Exp Med Biol 2019;1210:171-84.
11. Wang L, Xu M, Kao CY, Tsai SY, Tsai MJ. Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of
FOXA1. J Clin Invest 2020;130:1782-92.
12. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis,
and antiandrogen resistance. Science 2017;355:78-83.
13. Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and
RB1-deficient prostate cancer. Science 2017;355:84-8.
14. Jaratlerdsiri W, Chan EKF, Gong T, Petersen DC, Kalsbeek AMF, et al. Whole-genome sequencing reveals elevated tumor mutational
burden and initiating driver mutations in african men with treatment-naive, high-risk prostate cancer. Cancer Res 2018;78:6736-46.
15. Zolotovskaia MA, Sorokin MI, Petrov IV, Poddubskaya EV, Moiseev AA, et al. Disparity between inter-patient molecular heterogeneity
and repertoires of target drugs used for different types of cancer in clinical oncology. Int J Mol Sci 2020;21.
16. Su X, Long Q, Bo J, Shi Y, Zhao LN, et al. Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
Prostate 2020;80:508-17.
17. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in
patients with multiple types of cancer. J Clin Invest 2005;115:1503-21.
18. Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, et al. USP22 regulates oncogenic signaling pathways to drive lethal
cancer progression. Cancer Res 2014;74:272-86.
19. McCann JJ, Vasilevskaya IA, Poudel Neupane N, Shafi AA, McNair C, et al. USP22 functions as an oncogenic driver in prostate cancer
by regulating cell proliferation and DNA Repair. Cancer Res 2020;80:430-43.
20. Pfoh R, Lacdao IK, Georges AA, Capar A, Zheng H, et al. Crystal structure of USP7 ubiquitin-like domains with an ICP0 peptide reveals
a novel mechanism used by viral and cellular proteins to target USP7. PLoS Pathog 2015;11:e1004950.
21. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev
Biochem 2009;78:363-97.
22. Sahtoe DD, Sixma TK. Layers of DUB regulation. Trends Biochem Sci 2015;40:456-67.
23. Espinosa JM. Histone H2B ubiquitination: the cancer connection. Genes Dev 2008;22:2743-9.
24. Poondla N, Chandrasekaran AP, Kim KS, Ramakrishna S. Deubiquitinating enzymes as cancer biomarkers: new therapeutic
opportunities? BMB Rep 2019;52:181-9.
25. Melo-Cardenas J, Zhang Y, Zhang DD, Fang D. Ubiquitin-specific peptidase 22 functions and its involvement in disease. Oncotarget
2016;7:44848-56.
26. Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C. Deubiquitinases in cancer: new functions and therapeutic options.
Oncogene 2012;31:2373-88.
27. Atanassov BS, Evrard YA, Multani AS, Zhang Z, Tora L, et al. Gcn5 and SAGA regulate shelterin protein turnover and telomere
maintenance. Mol Cell 2009;35:352-64.